FILTER

Refine your search with the following facets to narrow down your results.

4 Current news of Ganymed Pharmaceuticals

Ganymed’s IMAB362 Shows Strong Evidence of Single-Agent Activity in Phase IIa Trial in Gastroesophageal Cancer

30-May-2014 - Ganymed Pharmaceuticals AG announced that its Ideal Monoclonal Antibody IMAB362 demonstrated significant safety and therapeutic benefits in a Phase IIa trial in gastroesophageal cancer (GEC). The trial involved 54 patients who had exhausted all other therapeutic options.“This study establishes ...

monoclonal antibodies phase IIa studies

Clinical Phase I Results of GANYMED's iMAB362 Antibody Demonstrate Excellent Safety

06-Aug-2010 - A clinical first-in-human Phase I multi center study with GANYMED's monoclonal antibody iMAB362 demonstrated excellent safety up to a dosis of 1g/sqm in gastro-esophageal cancer patients. iMAB362 targets GANYMED's proprietary cell surface antigen Claudine 18.2, which is present in 70% of all ...

antibodies gastric cancer Krebs +2

Dr. Thomas M. Rinderknecht chairs Supervisory Board of GANYMED

13-Oct-2006 - GANYMED Pharmaceuticals AG announced the appointment of Dr. Thomas M. Rinderknecht as new Chairman of the Supervisory Board and the election of Dr. Alfred Scheidegger as new member of the Supervisory Board. Mr. Rinderknecht also invested an undisclosed amount in a second closing of GANYMED's ...

Felix Switzerland

GANYMED lead antibodies show excellent efficacy and safety in mouse tumor models

10-Apr-2006 - GANYMED Pharmaceuticals AG announced that several monoclonal lead antibodies directed against the company's GC182 cancer target have shown excellent efficacy against solid human tumors in mouse xenograft models. No toxicity was observed. The results fully confirm earlier experiments, where ...

antibodies cell cultures gastric cancer +4